Medtronic collaborates with Samsung to develop a neuromodulation implantable app for smart devices
Although the medical device giant Medtronic is not an ordinary consumer, it still hopes to cooperate with Samsung to integrate the company's existing medical devices into consumer smart devices. In June of this year, the two companies collaborated to develop a portable smart device for diabetes, and now the two companies have developed an implantable app for neuromodulation. Based on current partnerships, Medtronic and Samsung Electronics America will jointly develop digital medical solutions for neuromodulation patients, including solutions for chronic pain, movement disorders, incontinence and other diseases. The program makes it easier for doctors and patients to use Android phones and tablets to manage treatments, track symptoms and monitor data wirelessly; in general, neuromodulation devices have dedicated controllers, and device-related data is downloaded, analyzed, and shared. The process is very complicated, the original intention of the design is to allow the two companies to better simplify the process. Dave Rhew, chief marketing officer of Samsung Electronics, said in a statement that Samsung is currently working to understand how people use high technology to provide innovation for healthcare. These solutions will provide advanced and convenient tools to better help patients. We conduct health management and these tools will be used to transmit safe and reliable data to doctors in real time. The initial collaboration on diabetes equipment focused on the previous plan, in which the two companies aimed to develop a new mobile app that is compatible with Samsung devices to help diabetics monitor insulin pumps and observe continuous glucose monitoring sensor data this year. In September, Medtronic developed a new MiniMed app based on the partnership. In the last quarter of this year, the field of neuromodulation brought US$485 million in revenue to Medtronic, a slight increase over the same period, and this area is also the business scope of Medtronic's rehabilitation therapy, but it is also the weakest business area. Greater growth comes from the field of neurovascular and surgical techniques, and one of the highlights of Medtronic's neuromodulation field is the deep brain stimulation device. Tom Tefft, general manager of the neuromodulation business at Medtronic, said that although the partnership with Samsung can improve the patient's treatment efficiency by developing digital solutions that connect patients and health care providers in real time, the current collaboration is individualized for the first time. Patient care is a step forward and is a new step in improving patient health and developing new technologies that are easier for patients to use. Mushrooms Xi'an complex bio-tech CO.,LTD. , https://www.complexpowder.com